Associated Genetic Biomarkers
NCI Definition: An adenocarcinoma that arises from the ovary. It is the most common type of ovarian carcinoma. It includes the serous adenocarcinoma, mucinous adenocarcinoma, clear cell adenocarcinoma, and endometrioid adenocarcinoma. 
Ovarian adenocarcinomas most frequently harbor alterations in TP53, KRAS, CCNE1, PIK3CA, and NF1 .
TP53 Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, TP53 Exon 5 Mutation, and TP53 Exon 8 Mutation are the most common alterations in ovarian adenocarcinoma .
There are 9 clinical trials for ovarian adenocarcinoma, of which 6 are open and 3 are completed or closed. Of the trials that contain ovarian adenocarcinoma as an inclusion criterion, 3 are phase 1 (2 open), 4 are phase 1/phase 2 (2 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open).
BRCA1 and BRCA2 are the most frequent gene inclusion criteria for ovarian adenocarcinoma clinical trials .
Carboplatin, paclitaxel, and anlotinib are the most common interventions in ovarian adenocarcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.